amphetamine has been researched along with malondialdehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| El-Sayed El-Sayad, M; El-Sayed El-Sisi, A; Osman, EY; Sayed Ramadan, E; Sokkar, SS | 1 |
2 other study(ies) available for amphetamine and malondialdehyde
| Article | Year |
|---|---|
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Combination; Fatty Acids, Omega-3; Male; Malondialdehyde; Maze Learning; Rats; Risperidone; Schizophrenia; Tumor Necrosis Factor-alpha | 2016 |